Rising Autoimmune Demand And China's Healthcare Modernization Will Fuel Breakthroughs
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
05 Aug 25
Updated
16 Aug 25
AnalystHighTarget's Fair Value
HK$23.85
17.8% undervalued intrinsic discount16 Aug
HK$19.60
1Y
330.8%7D
12.5%